NFE2L2 and endometrial carcinoma: In conclusion, our work suggests that NFE2L2/KEAP1 mutations leading to a strong NRF2 activation is a rare event in endometrial carcinoma, and that a subset of TP53/CNH-like endometrial carcinoma with serous histology have low NQO1 expression, that could be related to a NRF2/TP53 cooperation.